Nirav R. Kapadia Email and Phone Number

▪ Manage and support chemical process development for pipeline candidates. ▪ Critically analyze process and analytical data to resolve key challenges in non-cGMP and cGMP synthesis of advanced intermediates and API. ▪ Propose new synthetic routes and/or changes to the existing routes and assist in the development of improved processes. ▪ Plan and forecast drug substance activities by working with internal and external stakeholders to achieve program milestones. ▪ Collaborate with internal functional groups (AD, DP, DMPK, QC, RA). ▪ Lead external drug substance development - provide technical guidance and oversight, set quality guidelines, manage budget and timelines. ▪ Participate in the evaluation, selection and approval of new CDMOs.

𝐂𝐡𝐞𝐦𝐢𝐜𝐚𝐥 𝐏𝐫𝐨𝐜𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 ▪ Route scouting, route optimization, optimization of isolation conditions and identification and control of impurities for advanced intermediates, lead candidates and APIs. ▪ Establish in-process controls and identify critical reaction parameters. ▪ Perform use tests to support validation of chemical processes. (EasyMax to multi-kilo scale).

𝗗𝗲𝘀𝗶𝗴𝗻 𝗮𝗻𝗱 𝘀𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘀 𝗼𝗳 𝘀𝗺𝗮𝗹𝗹 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗼𝗳 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝘂𝗱𝗶𝗲𝗱 𝗸𝗶𝗻𝗮𝘀𝗲𝘀 𝗼𝗳 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝗰𝗲 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗔𝗔𝗞𝟭/𝗕𝗜𝗞𝗘, 𝗚𝗔𝗞, 𝗡𝗘𝗞𝟱, 𝗡𝗘𝗞𝟵 𝗮𝗻𝗱 𝗣𝗥𝗞𝗗▪ Designed, synthesized, purified and characterized novel small molecule kinase inhibitors. ▪ Scaled up key intermediates and targeted compounds to support in vivo studies. ▪ Generated Structure Activity Relationship (SAR) data through rational design and synthesis of inhibitors of understudied kinases. ▪ Synthesized novel kinase binding scaffolds to support early lead discovery for inhibitors of understudied kinases. ▪ Collaborated with global SGC sites and multiple academic collaborators across 4 continents for advancement of chemical probes as well as discovery targets. ▪ Key Achievements: Designed and synthesized an array of novel 4-anilino quinazoline compounds which resulted in the identification of several pan-PRKD inhibitors along with multiple negative control compounds. Distributed to several academic labs, this set of compounds helped elucidate the function and implication of PRKD famiily of kinases in melanoma, tuberculosis, fungal infections and lysosomal functions.Conducted an exhaustive survey of inhibitors targeting the Nek family of kinases. Co-authored manuscript detailing the biological significance of the Nek family of kinases and chemical starting points to target individual Nek kinases.

𝗗𝗲𝘀𝗶𝗴𝗻 𝗔𝗻𝗱 𝗦𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘀 𝗢𝗳 𝗔𝗽𝗼𝗿𝗽𝗵𝗶𝗻𝗲 𝗜𝗻𝘀𝗽𝗶𝗿𝗲𝗱 𝗟𝗶𝗴𝗮𝗻𝗱𝘀 𝗙𝗼𝗿 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗔𝘁 𝗖𝗡𝗦 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿𝘀▪ Initiated a systematic Structure Activity Relationship (SAR) study to improve the potency and selectivity of the aporphine alkaloid “𝘕𝘢𝘯𝘵𝘦𝘯𝘪𝘯𝘦” at the 5-HT2A receptor that led to the discovery of a novel aporphine compound with 5-HT2A antagonist activity. ▪ Explored the effect of C-4 phenyl substitution on the aporphine core and identified the first known aporphine alkaloid to have affinity for the 5-HT2B receptor.▪ Tested the tolerance of oxygen substitution on the aporphine core by developing a novel method for the synthesis of novel aporphinoid-Isochroman heterocycles. ▪ Discovered a new method for the synthesis of phenanthrene alkaloids via isochroman heterocycles. ▪ Synthesized a series of tris-(phenylalkyl)amine analogs that displayed high affinity for the 5-HT2B receptor with modest selectivity versus 5-HT2A and 5-HT2C receptors.▪ Using ICM-Pro and AutoDock Vina, performed molecular docking of aporphine alkaloids on to the 5-HT2A receptor for binding mode analysis and retrospective explanation of affinity.